GrayMatters Health recently received 510(k) clearance from the FDA to market its flagship product, which is a self-neuromodulation digital therapy for PTSD. The device uses neurofeedback on specific biomarkers to help patients identify and utilize their own mental strategy for lowering their emotional response.
A bipartisan group of House representatives introduced the Drug Price Transparency in Medicaid Act on Friday. The bill would ban spread pricing in Medicaid programs.
Zus Health Jonathan Bush's health data platform that provides patient information at the point of care recently closed a $40 million funding round. It also announced a partnership with Elation Health, a company that sells its EHR and other technology solutions to primary care providers. Elation will be integrating Zus' API into its own data collaboration systems.
BioNTech is expanding its cancer immunotherapy scope by partnering with OncoC4 on clinical testing of its lead drug. The antibody was designed to offer a safety edge over other CTLA-4-blocking drugs it's on track for a Phase 3 test in non-small cell lung cancer.